

<p>Informazione Regolamentata n. 20279-14-2026</p>	<p>Data/Ora Inizio Diffusione 12 Maggio 2026 11:36:18</p>	<p>Euronext Growth Milan</p>
--	---	------------------------------

Societa' : VALTECNE

Utenza - referente : VALTECNENSS01 - -

Tipologia : 3.1

Data/Ora Ricezione : 12 Maggio 2026 11:36:18

Data/Ora Inizio Diffusione : 12 Maggio 2026 11:36:18

Oggetto : VALTECNE: CONSOLIDATED QUARTERLY REVENUES EXCEED € 10 MILLION FOR THE FIRST TIME

Testo del comunicato

Vedi allegato



PRESS RELEASE

VALTECNE: CONSOLIDATED QUARTERLY REVENUES EXCEED € 10 MILLION FOR THE FIRST TIME
STRONG GROWTH PERFORMANCE OF THE MEDICAL BUSINESS LINE, IN LINE WITH THE COMPANY'S
STRATEGY, DRIVEN BY THE CORE ORTHOPAEDIC AND DENTAL BUSINESS OF SUBSIDIARY UTILITÀ
INDUSTRIAL BUSINESS LINE REVENUES UP 17%, THANKS TO THE CLEAR MARKET RECOVERY

Berbenno di Valtellina (SO), 12 May 2026 – The Board of Directors of **Valtecne S.p.A.** (ISIN IT0005532525, ticker VLT.IM) – a company operating in the field of high-precision mechanics for medical devices and industrial applications – met today and reviewed and approved the revenues as of March 31, 2026, which have not been audited. Consolidated revenues amounted to € 10.3 million as of March 31, 2026 (€ 9.4 million as of March 31, 2025), while stand-alone revenues amounted to € 8.8 million as of March 31, 2026 (€ 7.9 million in the same period of 2025).

Paolo Mainetti, Chief Executive Officer of Valtecne S.p.A., commented: *“Exceeding the threshold of €10 million in quarterly revenues for the first time represents a significant milestone for our Group and confirms the effectiveness of the strategy pursued over recent years. The growth of the Medical business line, driven by the core orthopaedic and dental business, together with the signs of recovery in the industrial segment, demonstrates the strength of our positioning and our ability to respond effectively to customer needs. To support this development phase, we are continuing with determination our investments in digitalisation, innovation of production processes and workforce strengthening, alongside an intense commercial business development activity aimed at expanding the Group’s growth opportunities, also thanks to the contribution of Luigi Ferrari, Senior Advisor who joined the Company at the end of 2025. The objective is to further consolidate our leadership in high-precision mechanics applied to medical devices”.*

1Q 2026 CONSOLIDATED					
SALES REVENUES (€/thousands)	31/03/2026	% of total	31/03/2025	% of total	Chg %
Medical Business line	7,546	73.6%	7,043	75.3%	7.1%
Industrial Business line	2,705	26.4%	2,314	24.7%	16.9%
Total	10,251	100%	9,357	100%	9.6%

At consolidated level, total revenues amounted to € 10.3 million, up by +9.6%. Specifically, the Medical business line recorded growth of +7.1%, consistent with the trend of recent years and with the Company’s



strategy, confirming the solidity of the core orthopaedic business and the dental business contributed by subsidiary Utilità. Overall, the Medical business line remained close to 75% of the Group's total revenues, positioning Valtecne S.p.A. as the leading Italian contract manufacturer in precision mechanics applied to medical devices.

The Industrial business line, on the other hand, reported revenue growth of +16.9%, supported by a clear market recovery trend following the significant contraction recorded between the end of 2023 and the first half of 2025. This reversal in the industrial market trend allows for improved production efficiency and generates a positive impact on operating margins.

Below is the breakdown of sales revenues of Valtecne S.p.A. (stand-alone) for the first three months of 2026 and the corresponding period of 2025, with the breakdown by business line.

1Q 2026 STAND-ALONE					
SALES REVENUES (€/thousands)	31/03/2026	% of total	31/03/2025	% of total	Chg %
Medical Business line	6,592	74.8%	5,970	75.9%	10.4%
Industrial Business line	2,221	25.2%	1,893	24.1%	17.3%
Total	8,814	100%	7,864	100%	12.1%

* * *

This press release is also available on the Company's website www.valtecne.com (section "Investors/Financial Press Releases") and on www.emarketstorage.it.

* * *

About Valtecne

Founded in 1983, Valtecne is a leading company in high-precision mechanics. It manufactures components used in the medical sector – particularly surgical instruments for orthopedics and implantable components – as well as in various industrial sectors such as power transmission, automotive, and energy. As of 31 December 2025, Valtecne reported Production Value of € 37.3 million and Adjusted EBITDA of € 9.7 million, corresponding to an EBITDA margin of 26.0%.

Contacts:

Euronext Growth Advisor – CFO SIM S.p.A.

ecm@cfosim.com

Phone. + 02 30343 1

Ufficio Stampa Corporate – CDR Communication

Martina Zuccherini martina.zuccherini@cdr-communication.it

Specialista – MIT SIM

trading-desk@mitsim.it

Phone +39 02 305 612 70

Fine Comunicato n.20279-14-2026

Numero di Pagine: 4